News Image

NASDAQ:NBIX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

By Mill Chart

Last update: Dec 22, 2023

Exploring Growth Potential: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and NEUROCRINE BIOSCIENCES INC has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected NEUROCRINE BIOSCIENCES INC on our screen for growth with base formation, suggesting it merits a closer look.

Unpacking NASDAQ:NBIX's Growth Rating

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:NBIX was assigned a score of 9 for growth:

  • NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 226.32%, which is quite impressive.
  • Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 66.75% on average per year.
  • NBIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.46%.
  • NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.91% yearly.
  • NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.63% yearly.
  • NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.00% yearly.

Understanding NASDAQ:NBIX's Health Score

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:NBIX has achieved a 7 out of 10:

  • An Altman-Z score of 9.72 indicates that NBIX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of NBIX (9.72) is better than 86.54% of its industry peers.
  • There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
  • NBIX has a Current Ratio of 2.39. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 2.34 indicates that NBIX has no problem at all paying its short term obligations.

Understanding NASDAQ:NBIX's Profitability

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 8 out of 10:

  • The Return On Assets of NBIX (6.71%) is better than 96.51% of its industry peers.
  • NBIX has a better Return On Equity (9.54%) than 95.68% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 12.95%, NBIX belongs to the top of the industry, outperforming 97.01% of the companies in the same industry.
  • The last Return On Invested Capital (12.95%) for NBIX is above the 3 year average (12.37%), which is a sign of increasing profitability.
  • NBIX has a better Profit Margin (10.71%) than 96.18% of its industry peers.
  • In the last couple of years the Profit Margin of NBIX has grown nicely.
  • The Operating Margin of NBIX (19.50%) is better than 96.68% of its industry peers.
  • Looking at the Gross Margin, with a value of 97.82%, NBIX belongs to the top of the industry, outperforming 97.34% of the companies in the same industry.

Looking at the Setup

In addition to the Technical Rating, ChartMill provides a Setup Rating for each stock. This rating, ranging from 0 to 10, assesses the level of consolidation in the stock based on multiple short-term technical indicators. Currently, NASDAQ:NBIX has a 7 as its setup rating, indicating its current consolidation status.

NBIX has an excellent technical rating and also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry. There is very little resistance above the current price.

More Strong Growth stocks can be found in our Strong Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of NBIX

For an up to date full technical analysis you can check the technical report of NBIX

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (4/26/2024, 7:05:57 PM)

After market: 135.99 0 (0%)

135.99

-1.77 (-1.28%)

NBIX News

News Image3 days ago - Investor's Business DailyStock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

News Image5 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap...

News Image5 days ago - InvestorPlace3 Red-Hot Biotech Rockets Blasting Off in 2024

The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.

News Image6 days ago - Investor's Business DailyNo. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win

The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.

News Image13 days ago - Sentia Medical Sciences, Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
News Image18 days ago - ChartmillWhy NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.

News Image19 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...

News Image19 days ago - ChartmillFor those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

News Imagea month ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...

News Imagea month ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...

News Imagea month ago - Investor's Business DailyS&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

DexCom, Blackstone and Royal Caribbean head this list of five stocks.

News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

NBIX Links
Follow us for more